论文期刊

取消

高级检索

检索历史清除

首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.

导出 OA

翻译打印收藏纠错

作者： Kendra,Sweet ^[1] ; Rami,Komrokji ^[2] ; Eric,Padron ^[2] ; Christopher L,Cubitt ^[3] ; Joel G,Turner ^[4] ; Junmin,Zhou ^[5] ; Alan F,List ^[2] ; David A,Sallman ^[2] ; Jana L,Dawson ^[6] ; Daniel M,Sullivan ^[4] ; Julio,Chavez ^[2] ; Bijal D,Shah ^[2] ; Jeffrey E,Lancet ^[2]

作者单位： Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. kendra.sweet@moffitt.org. ^[1] Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. ^[2] Department of Translational Research, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. ^[3] Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. ^[4] Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. ^[5] Department of Experimental Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. ^[6]

主题词成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);阿糖胞苷(Cytarabine);柔红霉素(Daunorubicin);女(雌)性(Female);人类(Humans);肼类(Hydrazines);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);中年人(Middle Aged);存活率(Survival Rate);组织分布(Tissue Distribution);治疗结果(Treatment Outcome);三唑类(Triazoles)

DOI 10.1158/1078-0432.CCR-19-2169

PMID 31636097

发布时间 2021-01-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览3

Clinical cancer research : an official journal of the American Association for Cancer Research

Clinical cancer research

2020年26卷1期

54-60页

相似文献

中文期刊
外文期刊
学位论文
会议论文

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)
|
客服邮箱：yiyao@wanfangdata.com.cn

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信

万方医学小程序

关于我们网站地图知识产权

北京万方数据股份有限公司

万方数据电子出版社

京ICP证010071号

京公网安备11010802020237号

京ICP备08100800号-1

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

new翻译充值订阅收藏移动端

官方微信

万方医学小程序

调查问卷